

## Supplemental Material

### Methods

All experimental studies using human samples comply with the Declaration of Helsinki and were approved by the local ethics committee (*Comité de Protection des Personnes* [CPP] EST-II n°: 18.06.06). All patients gave informed consent before the study.

**Isolation, and culture of primary Human pulmonary endothelial cells (ECs):** Human pulmonary ECs were isolated and cultured as previously described <sup>16,17</sup>. The isolated ECs were strongly positive for acetylated low-density lipoprotein coupled to Alexa 488 (Alexa488-Ac-LDL), von Willebrand factor (vWF), CD31, and for *Ulex europaeus* agglutinin-1 (UEA-1) and negative for alpha-smooth muscle actin ( $\alpha$ -SMA). Cells were routinely tested for mycoplasma and used at early passages  $\leq 5$ .

**Immunofluorescent staining and microscopy:** Immunofluorescent staining for NF2 (1:100; sc-55575 from Santa Cruz),  $\alpha$ -SMA (1:200; sc-32251 from Santa Cruz), and vWF (1:200; A0082 from DAKO) were performed in lung paraffin sections as previously described <sup>11,12</sup>. Briefly, lung sections (5  $\mu$ m of thickness) were deparaffinized and incubated with the antigen retrieval buffer. Then, sections were saturated with blocking buffer and incubated overnight with specific antibodies, followed by addition of the corresponding secondary fluorescent-labelled antibodies (Thermo Fisher Scientific, Saint-Aubin, France). Nuclei were labelled using DAPI (Thermo Fisher Scientific). Mounting was performed using ProLong Gold antifade reagent (Thermo Fisher Scientific). All images were taken using a LSM700 confocal microscope (Zeiss, Marly-le-Roi, France).

**Western Immunoblot:** Cells were homogenized and sonicated in PBS containing protease and phosphatase inhibitors (Sigma-Aldrich). Fifty  $\mu$ g of protein extract were used to detect NF2 (sc-55575; 1:200) by SDS-PAGE as previously described <sup>11,12</sup>. Statistical significance was tested

using the nonparametric Mann-Whitney U test. Significant difference was assumed at a p value of  $< 0.05$ . Analyses were performed using GraphPad Prism v5.0, La Jolla, CA.

## References

11. Savale L, Akagi S, Tu L, et al. Serum and Pulmonary Uric Acid in Pulmonary Arterial Hypertension. *Eur Respir J*. 2021.
12. Tamura Y, Phan C, Tu L, et al. Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. *The Journal of clinical investigation*. 2018;128(5):1956-1970.